sch 34826 has been researched along with Heart Failure in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fyhrquist, F; Helin, K; Hohenthal, U; Tikkanen, I | 1 |
| Helin, K | 1 |
| Sybertz, EJ | 1 |
1 review(s) available for sch 34826 and Heart Failure
| Article | Year |
|---|---|
SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Dioxolanes; Dipeptides; Drug Synergism; Heart Failure; Humans; Hypertension; Neprilysin; Prodrugs; Rats | 1991 |
2 other study(ies) available for sch 34826 and Heart Failure
| Article | Year |
|---|---|
Inhibition of either angiotensin-converting enzyme or neutral endopeptidase induces both enzymes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Captopril; Dioxolanes; Dipeptides; Disease Models, Animal; Enzyme Induction; Heart Failure; Kidney; Ligation; Lung; Male; Neprilysin; Organ Size; Peptidyl-Dipeptidase A; Radioimmunoassay; Rats; Rats, Wistar; Regression Analysis; Renin | 1994 |
Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: renal and hormonal effects.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Chronic Disease; Cyclic GMP; Dioxolanes; Dipeptides; Drug Therapy, Combination; Heart Failure; Kidney; Male; Neprilysin; Rats; Rats, Wistar | 1993 |